Digna to use Flamel's delivery tech in new products

Two drug-delivery technologies developed by the French company Flamel Technologies will play starring roles in a new deal the company has reached with the Spanish company Digna Biotech. Digna will use Flamel's Medusa and Micropump technologies in three initial Digna products. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.